Free Access
Med Sci (Paris)
Volume 29, Number 5, Mai 2013
Page(s) 457 - 460
Section Nouvelles
Published online 28 May 2013
  1. Beck A, Wagner-Rousset E, Wurch T, Corvaia N. Anticorps thérapeutiques et dérivés : une palette de structures pour une pléthore d’indications. Med Sci (Paris) 2009 ; 25 : 1024–1032. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010 ; 10 : 345–352. [CrossRef] [PubMed] [Google Scholar]
  3. Berry JD, Gaudet RG. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. Nat Biotech 2011 ; 28 : 489–501. [Google Scholar]
  4. Klinguer-Hamour C, Caussanel V, Beck A. Anticorps thérapeutiques et maladies infectieuses. Med Sci (Paris) 2009 ; 25 : 1116–1120. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 ; 477 : 466–470. [CrossRef] [PubMed] [Google Scholar]
  6. Gros L, Dreja H, Fiser AL, et al. Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol 2005 ; 79 : 6272–6280. [CrossRef] [PubMed] [Google Scholar]
  7. Gros L, Pelegrin M, Michaud HA, et al. Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol 2008 ; 82 : 1339–1349. [CrossRef] [PubMed] [Google Scholar]
  8. Michaud HA, Gomard T, Gros L, et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010 ; 6 : e1000948. [CrossRef] [PubMed] [Google Scholar]
  9. Nasser R, Pelegrin M, Michaud HA, et al. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010 ; 84 : 10169–10181. [CrossRef] [PubMed] [Google Scholar]
  10. Nasser R, Pelegrin M, Plays M, et al. Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood 2013 ; 121 : 1102–1111. [CrossRef] [PubMed] [Google Scholar]
  11. Ng CT, Jaworski JP, Jayaraman P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010 ; 16 : 1117–1119. [CrossRef] [PubMed] [Google Scholar]
  12. Watkins JD, Siddappa NB, Lakhashe SK, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade, elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011 ; 6 : e18207. [CrossRef] [PubMed] [Google Scholar]
  13. Bossart KN, Zhu Z, Middleton D, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 2009 ; 5 : e1000642. [CrossRef] [PubMed] [Google Scholar]
  14. Deligne C, Teillaud JL. Le double visage des anticorps monoclonaux en oncologie. Med Sci (Paris) 2013 ; 29 : 57–63. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.